EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Chemokines and pain mechanisms

Catherine Abbadie, Sonia Bhangoo, Yves De Koninck, Marzia Malcangio, Stéphane Melik-Parsadaniantz, Fletcher A White

Brain Research Reviews · 2009-04 · 60 (1) · 125-134

DOI: 10.1016/j.brainresrev.2008.12.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain Research Reviews, 2009-04. Verfasst von Catherine Abbadie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA. catherine_abbadie@merck.com. Die Arbeit wurde bisher 249-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, Wellcome Trust, NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of new therapeutic approaches to the treatment of painful neuropathies requires a better understanding of the mechanisms that underlie the development of these chronic pain syndromes. It is now well established that astrocytic and microglial cells modulate the neuronal mechanisms of chronic pain in spinal cord and possibly in the brain. In animal models of neuropathic pain following peripheral nerve injury, several changes occur at the level of the first pain synapse between the central terminals of sensory neurons and second order neurons. These neuronal mechanisms can be modulated by pro-nociceptive mediators released by non neuronal cells such as microglia and astrocytes which become activated in the spinal cord following PNS injury. However, the signals that mediate the spread of nociceptive signaling from neurons to glial cells in the dorsal horn remain to be established. Herein we provide evidence for two emerging signaling pathways between injured sensory neurons and spinal microglia: chemotactic cytokine ligand 2 (CCL2)/CCR2 and cathepsin S/CX3CL1 (fractalkine)/CX3CR1. We discuss the plasticity of these two chemokine systems at the level of the dorsal root ganglia and spinal cord demonstrating that modulation of chemokines using selective antagonists decrease nociceptive behavior in rodent chronic pain models. Since up-regulation of chemokines and their receptors may be a mechanism that directly and/or indirectly contributes to the development and maintenance of chronic pain, these molecular molecules may represent novel targets for therapeutic intervention in sustained pain states.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnimalsCathepsinsChemokine CCL2ChemokinesGanglia, SpinalHumansNociceptorsPainPosterior Horn CellsReceptors, ChemokineSignal Transduction

Substanzen

Chemokine CCL2ChemokinesReceptors, ChemokineCathepsinscathepsin S

Autor:innen und Institutionen

  • Department of Immunology, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA. catherine_abbadie@merck.com

Förderung

  • NIDA NIH HHS
  • Wellcome Trust
  • NIMH NIH HHS
  • NINDS NIH HHS

Zitieren

APA

Abbadie, C., Bhangoo, S., De Koninck, Y., Malcangio, M., Melik-Parsadaniantz, S., & White, F. A. (2009). Chemokines and pain mechanisms. Brain Research Reviews, 60(1), 125-134. https://doi.org/10.1016/j.brainresrev.2008.12.002

Vancouver

Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S, White FA. Chemokines and pain mechanisms. Brain Research Reviews. 2009;60(1):125-134. doi:10.1016/j.brainresrev.2008.12.002

BibTeX
@article{Abbadie2009,
  author = {Abbadie, Catherine and Bhangoo, Sonia and De Koninck, Yves and Malcangio, Marzia and Melik-Parsadaniantz, Stéphane and White, Fletcher A},
  title = {Chemokines and pain mechanisms},
  journal = {Brain Research Reviews},
  year = {2009},
  volume = {60},
  number = {1},
  pages = {125--134},
  doi = {10.1016/j.brainresrev.2008.12.002}
}
Kostenlos starten →